Cancer Network spoke with Steven H. Lin, MD, PhD, of MD Anderson Cancer Center, on the findings of a phase II trial of atezolizumab plus chemoradiation therapy in locally advanced non-small-cell lung cancer.
Cancer Network spoke with Nathan A. Pennell, MD, PhD, of Cleveland Clinic at ASCO 2019 regarding current use of and barriers to molecular testing in NSCLC.
Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope at ASCO 2019 about data on emerging MET inhibitors in the treatment of lung cancer patients.
In this video, Dr. McFarland of Memorial Sloan-Kettering Cancer Center spoke with Cancer Network at ASCO 2019 about depression in lung cancer and dopamine as potential therapy.
Cancer Network spoke with Tina Cascone, MD, of MD Anderson Cancer Center, at ASCO 2019 about combination checkpoint blockade in the pre-surgical setting for early-stage NSCLC.
Cancer Network spoke with Mehmet Sitki Copur, MD, FACP, medical oncologist at the Morrison Cancer Center, about the most exciting research presented at ASCO in 2019.
Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.
Cancer Network spoke with Hank Schmidt, MD, about the 10-year follow-up results of the EORTC AMAROS trial of radiotherapy vs surgery of the axilla in breast cancer patients with a positive sentinel node.
Cancer Network spoke with Jennie Williams, PhD, and Jenny Paredes, a PhD student, about how tumor biology impacts chemotherapy response in African American vs Caucasian patients.
Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma
Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.